Regulatory Gap : Regulatory bodies (the FDA and European Medicines Agency (EMA)) classify BPC-157 as a research compound, prohibiting its use as an approved therapeutic
Proprits et effets recherchs Action antioxydante Diffrentes molcules dites actives de loxygne, comme les peroxydes dhydrogne, reprsentent une des premires sources de stress oxydatif cellulaire
A phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Subjects continued following the low glutamate diet during this challenge period to ensure that the only glutamate they were receiving was during the MSG challenge week
doi: 10.3389/fendo.2014.00056 Received 20 March 2014 Accepted 07 April 2014 Published 22 April 2014 Volume 5 - 2014 Edited by Rosaria Meccariello, University of Naples Parthenope, Italy Reviewed by Rosanna Chianese, Second University of Naples, Italy
M.ShankarS